Search

Kurt Iver Kamrud

from Olathe, KS
Age ~59
Get Report
Also known as:
Kurt I Kamrud, Kurt Iver Dr Kamrud, Kurt T Kamrud, Kurt L Kamrud, Kurt I Kumru, Kurt Carmen, Kurt Rokke, Kurt D
Related to:
Susan K Hendricks, 61Carmen Kamrud, 57Christina Swanson, 51Tricia Fossen, 54Christopher Thomas, 61
Connected to:
Akm Kamruzzaman, 47Kristen Kams, 54Morris KamshaCase Y Kamshad, 41Thomas J Kamsickas, 53Nathan Kamsler, 38Linda K Kamstra, 77Michael P Kamstra, 38Tore Kamsvaag, 62Meredith G Kamuda, 50

Kurt Kamrud Phones & Addresses

  • Olathe, KS
  • San Diego, CA
  • 2209 Winpost Ln, Apex, NC 27502 (919) 303-1242
  • Frederick, MD
  • 115 Solstice Cir, Cary, NC 27513
  • Fort Collins, CO
  • Ballwin, MO
  • Wade, NC
  • 2209 Winpost Ln, Apex, NC 27502

Resumes

Resumes

Kurt Kamrud Photo 1

Director Genomic Platforms

View page
Location:
San Diego, CA
Industry:
Veterinary
Work:
Synthetic Genomics Vaccines Inc - 11149 North Torrey Pines Road, La Jolla, CA 92037 since Jun 2013
Technology Integration Lead
Harrisvaccines 2010 - Jun 2013
Vice President of Research and Chief Scientific Officer
AlphaVax, Inc Nov 2000 - Jun 2010
Director of Discovery Reseach
USAMRIID 1996 - 2000
Microbiologist
Education:
Colorado State University 1992 - 1996
Ph.D., Microbiology, Virology
Skills:
Vaccines
Laboratory
Dna
Molecular Biology
Life Sciences
Virology
Biotechnology
Infectious Diseases
Cell Culture
Genetics
Immunology
Microbiology
Elisa
Pcr
Assay Development
Clinical Development
Cell
Bacterial Culture
Lifesciences
Influenza
Laboratory Skills
Kurt Kamrud Photo 2

Kurt Kamrud

View page

Publications

Us Patents

Alphavirus Particles And Methods For Preparation

View page
US Patent:
7078218, Jul 18, 2006
Filed:
Dec 12, 2003
Appl. No.:
10/734609
Inventors:
Jonathan F. Smith - Cary NC, US
Kurt Kamrud - Apex NC, US
Sergey Dryga - Chapel Hill NC, US
Harold Alterson - Cary NC, US
Jon Rayner - Apex NC, US
Kim Butler - Cary NC, US
Maureen F. Maughan - Durham NC, US
Assignee:
AlphaVax, Inc. - Research Triangle Park NC
International Classification:
C12N 7/00
C12N 7/02
C12N 15/00
C12N 15/63
C12N 15/87
US Classification:
4352351, 435239, 4353201, 435 693, 435455, 435456, 435457, 435461
Abstract:
Provided herein are methods for producing alphavirus replicon particles in high yield; replicon RNAs are electroporated into permissive cells, where the cells are at a relatively high density, together with at least one helper nucleic acid providing the necessary functions for packaging. After a growth period in appropriate medium, alphavirus replicon particles are harvested from the surfaces of the cells in which they were produced using a salt wash in which the salt concentration is from about 0. 2 to about 5 M sodium chloride, calcium chloride, magnesium chloride, potassium chloride, ammonium acetate, ammonium bicarbonate, among others. After dilution, if necessary, the particles can be purified by a suitable chromatographic technique.

Alphavirus Replicon Vector Systems

View page
US Patent:
7425337, Sep 16, 2008
Filed:
Mar 16, 2006
Appl. No.:
11/376901
Inventors:
Jonathan F. Smith - Cary NC, US
Kurt I. Kamrud - Apex NC, US
Jonathan O. Rayner - Apex NC, US
Sergey A. Dryga - Chapel Hill NC, US
Ian J. Caley - Durham NC, US
Assignee:
AlphaVax, Inc. - Research Triangle Park NC
International Classification:
A61K 39/12
C12N 15/64
C12N 5/02
US Classification:
4242181, 435325, 435 9142
Abstract:
The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.

Alphavirus Replicons And Helper Constructs

View page
US Patent:
7442381, Oct 28, 2008
Filed:
Mar 19, 2004
Appl. No.:
10/804331
Inventors:
Jonathan F. Smith - Cary NC, US
Kurt I. Kamrud - Apex NC, US
Jon O. Rayner - Apex NC, US
Assignee:
AlphaVax, Inc. - Research Triangle Park NC
International Classification:
A01N 63/00
A61K 39/12
C07H 21/04
US Classification:
4242181, 536 231, 424 931
Abstract:
The present invention provides a recombinant nucleic acid comprising: a first nucleic acid sequence encoding a 5′ alphavirus replication recognition sequence; at least one second nucleic acid sequence encoding an alphavirus nonstructural protein; at least one alphavirus subgenomic promoter; at least one IRES element; at least one heterologous nucleic acid; and a third nucleic acid encoding a 3′ alphavirus replication recognition sequence. Further provided are methods of making alphavirus particles comprising a recombinant nucleic acid of this invention and methods of using the compositions of this invention. Also provided is a recombinant helper nucleic acid comprising: a first nucleic acid sequence encoding a 5′ alphavirus replication recognition sequence; an alphavirus subgenomic promoter; an IRES element; a second nucleic acid encoding an alphavirus structural protein; and a third nucleic acid encoding a 3′ alphavirus replication recognition sequence.

Promoterless Cassettes For Expression Of Alphavirus Structural Proteins

View page
US Patent:
7850977, Dec 14, 2010
Filed:
Jun 20, 2008
Appl. No.:
12/143320
Inventors:
Kurt I. Kamrud - Apex NC, US
Jonathan F. Smith - Cary NC, US
Maureen Maughan - Durham NC, US
Assignee:
Alphavax, Inc. - Research Triangle Park NC
International Classification:
A61K 39/12
C12N 7/01
C12N 7/02
C12N 5/10
C12N 15/40
C12N 15/86
US Classification:
4241991, 4242181, 536 2372, 4352351, 4353201, 435325, 435239
Abstract:
The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3′ replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5′ and 3′ replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins.

Promoterless Cassettes For Expression Of Alpha Virus Structural Proteins

View page
US Patent:
8460913, Jun 11, 2013
Filed:
Jun 20, 2008
Appl. No.:
12/665497
Inventors:
Kurt I. Kamrud - Apex NC, US
Jonathan F. Smith - Cary NC, US
Maureen Maughan - Durham NC, US
Assignee:
Alpha Vax, Inc. - Research Triangle Park NC
International Classification:
C12N 7/02
US Classification:
4352351, 435239, 435462
Abstract:
The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3′ replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5′ and 3′ replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus non-structural proteins.

Multi-Antigenic Alphavirus Replicon Particles And Methods

View page
US Patent:
8617533, Dec 31, 2013
Filed:
May 6, 2008
Appl. No.:
12/116031
Inventors:
Jonathan F. Smith - Cary NC, US
Kurt Kamrud - Apex NC, US
Sergey Dryga - Chapel Hill NC, US
Ian Caley - Durham NC, US
Assignee:
AlphaVax, Inc. - Research Triangle Park NC
International Classification:
A01N 63/00
A61K 48/00
C12N 15/00
C12N 15/86
C12N 15/88
C12N 15/87
US Classification:
424 932, 435455, 435458, 435461, 435465
Abstract:
Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.

Alphavirus Replicon Vector Systems

View page
US Patent:
20030119182, Jun 26, 2003
Filed:
Sep 6, 2002
Appl. No.:
10/237302
Inventors:
Jonathan Smith - Cary NC, US
Kurt Kamrud - Apex NC, US
Jonathan Rayner - Apex NC, US
Sergey Dryga - Chapel Hill NC, US
Ian Caley - Durham NC, US
International Classification:
C12Q001/70
C12P021/06
C12P019/34
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
US Classification:
435/320100, 435/069100, 435/091100, 435/005000
Abstract:
The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication-competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.

Multi-Antigenic Alphavirus Replicon Particles And Methods

View page
US Patent:
20040208848, Oct 21, 2004
Filed:
Dec 12, 2003
Appl. No.:
10/735601
Inventors:
Jonathan Smith - Cary NC, US
Kurt Kamrud - Apex NC, US
Sergey Dryga - Chapel Hill NC, US
Ian Caley - Durham NC, US
International Classification:
A61K048/00
C12N015/861
US Classification:
424/093200, 435/457000
Abstract:
Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
Control profile
Kurt Iver Kamrud from Olathe, KS, age ~59 Get Report